Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia
08 mars 2018 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
SAN FRANCISCO, March 08, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc....
Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum
05 mars 2018 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
SAN FRANCISCO, March 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., an orphan specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings,...
MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231
01 mars 2018 06h00 HE
|
Amarantus Bioscience Holdings, Inc.
Allowed claims include the treatment of Type 1 and Type 2 DiabetesPatent protects exclusivity for MANF in diabetes inthe US into 2032 SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- via OTC PR...
Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding
26 févr. 2018 17h56 HE
|
Amarantus Bioscience Holdings, Inc.
At least 96% of eligible securities participating in Tender ExchangeCEO to present at BIOCOM Global Life Science Partnering Conference in San Diego SAN FRANCISCO, Feb. 26, 2018 (GLOBE NEWSWIRE) --...
Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s Disease
29 janv. 2018 09h00 HE
|
Amarantus Bioscience Holdings, Inc.
SAN FRANCISCO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries...
Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
23 janv. 2018 09h59 HE
|
Amarantus Bioscience Holdings, Inc.
Patent Issuance Opens Potential to genetically modify cells used to produce ESS Peer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs....
Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018
09 janv. 2018 10h59 HE
|
Amarantus Bioscience Holdings, Inc.
Convertible securities holders grant 45-day extension to complete Tender Exchange Elto Pharma recruiting seasoned management to lead "Go-Public" transaction Management...
Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
04 janv. 2018 09h45 HE
|
Amarantus Bioscience Holdings, Inc.
Patent Issuance Opens Potential to genetically modify cells used to produce ESSPeer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs....
Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data
03 janv. 2018 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
Patents extend MANF Therapeutics' exclusivity for use of MANF as a treatment and a biomarker for beta cell disorders in Europe and China into 2032List of diseases covered by patents include Type-1...
Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma
26 déc. 2017 07h30 HE
|
Amarantus Bioscience Holdings, Inc.
Patents extend MANF Therapeutics' exclusivity for MANF and CDNF treatment of retinal disorders in Europe into 2031Literature Watch "Super-MANF" article published in American Journal of Transplantation...